Cargando…

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy

SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) continues to have a poor prognosis unless a complete pathological response is achieved after neoadjuvant chemotherapy (NAC). The identification of prognostic factors would help to improve care. The evaluation of tumor-infiltrating lymphocyte (TIL)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giacchetti, Sylvie, Faucheux, Lilith, Gardair, Charlotte, Cuvier, Caroline, de Roquancourt, Anne, Campedel, Luca, Groheux, David, de Bazelaire, Cedric, Lehmann-Che, Jacqueline, Miquel, Catherine, Cahen Doidy, Laurence, Amellou, Malika, Madelaine, Isabelle, Reyal, Fabien, Someil, Laetitia, Hocini, Hamid, Hennequin, Christophe, Teixeira, Luis, Espié, Marc, Chevret, Sylvie, Soumelis, Vassili, Hamy, Anne-Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909288/ https://www.ncbi.nlm.nih.gov/pubmed/35267639 http://dx.doi.org/10.3390/cancers14051331

Ejemplares similares

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC
por: Campedel, Luca, et al.
Publicado: (2020)

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
por: Lehmann-Che, Jacqueline, et al.
Publicado: (2013)

Prognostic Impact of (18)FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer
por: Groheux, David, et al.
Publicado: (2012)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
por: Groheux, D, et al.
Publicado: (2013)

Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer
por: Bousquet, Guilhem, et al.
Publicado: (2017)

Comparison of characteristics and laboratory tests of COVID-19 hematological patients from France and Brazil during the pre-vaccination period: identification of prognostic profiles for survival
por: Faucheux, Lilith, et al.
Publicado: (2023)

A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer
por: Faucheux, L., et al.
Publicado: (2019)

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
por: Lehmann-Che, J, et al.
Publicado: (2011)

Comparison of Characteristics and Laboratory Tests of COVID 19-Hematological Patients from France and Brazil: Identification of Prognostic Driven Profiles
por: Alves, Lucas Bassolli de Oliveira, et al.
Publicado: (2021)

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
por: Cottu, P H, et al.
Publicado: (2001)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

A multivariate modeling framework to quantify immune checkpoint context-dependent stimulation on T cells
por: Karpf, Léa, et al.
Publicado: (2022)

Dose fractionation effects with negative pions
por: Bianchi, M, et al.
Publicado: (1980)

Definition of a novel breast tumor-specific classifier based on secretome analysis
por: Sirven, Philémon, et al.
Publicado: (2022)

(18)FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients
por: de Cremoux, Patricia, et al.
Publicado: (2018)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
por: Chevret, Sylvie, et al.
Publicado: (2023)

Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
por: Chevret, Sylvie, et al.
Publicado: (2023)

Neoadjuvant treatment: the future of patients with breast cancer
por: Reyal, F, et al.
Publicado: (2018)

Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study
por: de Bazelaire, Cédric, et al.
Publicado: (2011)

Low-dose polymyxin: an option for therapy of Gram-negative sepsis
por: Harm, Stephan, et al.
Publicado: (2016)

Colistin Loading Dose in Septic Patients with Gram Negative Infections
por: Alshaya, Abdulrahman I, et al.
Publicado: (2022)

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007)

Evaluation of Single Dose and Fractionated Dose of I-131 Radiolabeled Nanoparticles for Triple-Negative Breast Cancer Treatment
por: Marshall, Suphalak Khamruang, et al.
Publicado: (2023)

Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy
por: Dubois, Clémence, et al.
Publicado: (2019)

Incidence, risk factors, and outcomes of central venous catheter‐related thromboembolism in breast cancer patients: the CAVECCAS study
por: Debourdeau, Philippe, et al.
Publicado: (2017)

(18)FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis
por: Groheux, David, et al.
Publicado: (2017)

Negative Requests Within Hair Salons: Grammar and Embodiment in Action Formation
por: Horlacher, Anne-Sylvie
Publicado: (2022)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

Carbon Dioxide Inhalation Induces Dose-Dependent and Age-Related Negative Affectivity
por: Griez, Eric J., et al.
Publicado: (2007)

Cytochrome P-450-mediated herb and food–drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study
por: Gougis, P., et al.
Publicado: (2022)

Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma
por: Bousquet, Guilhem, et al.
Publicado: (2014)

220. Effectiveness of Piperacillin/tazobactam Loading Dose for Extended Infusion Dosing Among Patients with Gram-negative Bacteremia (EZ-LD)
por: Patel, Savan, et al.
Publicado: (2023)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
por: Bidard, François-Clément, et al.
Publicado: (2013)

Joint modeling of multivariate longitudinal data and the dropout process in a competing risk setting: application to ICU data
por: Deslandes, Emmanuelle, et al.
Publicado: (2010)

Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome
por: Vinnat, Valentin, et al.
Publicado: (2022)

Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation
por: Perreault, Sylvie, et al.
Publicado: (2022)

Emx2 is a dose-dependent negative regulator of Sox2 telencephalic enhancers
por: Mariani, J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_io1dce3lcroodegfjb4d6e1g0u